Franck Toledo

Prof. Franck Toledo

orcid

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2006 in Nature Reviews Cancer
Verified
Journal Article
Closed access
PDF file
FTFranck Toledo
Franck Toledo
GWGeoffrey M. Wahl
Geoffrey M. Wahl

1 April 1997 in Cell
Verified
Journal Article
Closed access
ACArnaud Coquelle
Arnaud Coquelle
EPEva Pipiras
Eva Pipiras
FTFranck Toledo
Franck Toledo
GBGérard Buttin
Gérard Buttin
MDMichelle Debatisse
Michelle Debatisse

1 July 2007 in The International Journal of Biochemistry & Cell Biology
Verified
Journal Article
Closed access
FTFranck Toledo
Franck Toledo
GWGeoffrey M. Wahl
Geoffrey M. Wahl

1 August 1998 in Molecular Cell
Verified
Journal Article
Closed access
ACArnaud Coquelle
Arnaud Coquelle
FTFranck Toledo
Franck Toledo
SSSabine Stern
Sabine Stern
ABAnne Bieth
Anne Bieth
MDMichelle Debatisse
Michelle Debatisse

1 April 2006 in Cancer Cell
Verified
Journal Article
Closed access
FTFranck Toledo
Franck Toledo
KKKurt A. Krummel
Kurt A. Krummel
CLCrystal J. Lee
Crystal J. Lee
CLChung-Wen Liu
Chung-Wen Liu
LRLuo-Wei Rodewald
Luo-Wei Rodewald
GWGeoffrey M. Wahl
Geoffrey M. Wahl

8 July 2005 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
KKKurt A. Krummel
Kurt A. Krummel
CLCrystal J. Lee
Crystal J. Lee
FTFranck Toledo
Franck Toledo
GWGeoffrey M. Wahl
Geoffrey M. Wahl
P53 is an unstable transcription factor that is mutated in a majority of human cancers. With a significant role in initiating cell elimination programs, a network has evolved to fine-tune P53 transcriptional output and prevent errant activation. Modifications of the C terminus have long been viewed as critical binary determinants of P53 stability or activation. However, these conclusions are based on in vitro transfection or biochemical analyses where the stoichiometries between P53 and its regulators are perturbed. Therefore, we tested the importance of the C-terminal regulatory region for P53 control in mice where the seven C-terminal lysines were changed to arginine ( Trp-53 7KR ). Surprisingly, the homozygous mutant mice are viable and phenotypically normal. We have functionally characterized the mutant protein in both MEFs and thymocytes, revealing the unexpected result that Trp-53 7KR exhibits a normal half-life and functions like WT P53 in cell cycle arrest and apoptosis, and in an E1A-ras xenograft tumor suppression assay. However, a significant difference is that P53 7KR is activated more easily by DNA damage in thymus than WT P53. Importantly, although MEFs encoding WT P53 spontaneously emerge from crisis to become immortal in a 3T3 growth protocol, we do not observe any such escape with the P53 7KR cells. We propose that the C-terminal modifications believed to be critical for proper P53 regulation are not essential, but contribute to a fine-tuning mechanism of homeostatic control in vivo .